Cephalon Inc. has dropped their patent infringement suit against Actavis Inc. over a generic version of Nuvigil®, a drug for narcolepsy. The decision came after Actavis made the decision not to produce a competing version of the drug, which treats sleep apnea and shift work sleep disorder in addition to narcolepsy. Cephalon is represented by Finnegan.
Press Release
October 6, 2026
Commentary
Federal Circuit Revives Whistleblower Complaint Over VA's AI Claims-Processing Tool
September 25, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Commentary
New Thomas Pink Womenswear Lines Strain ‘Pink’ Pact with Victoria’s Secret
September 21, 2026
Commentary
Uncrustables Fame Ruling Sets Up Functionality Fight Over Crimped Edge
September 11, 2026
Award/Ranking
September 11, 2026
Media Mention
Finnegan Opens First Texas Office with ‘Two Leaders with Genuine Local Roots'
September 7, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.